300122 智飞生物
已收盘 11-01 15:00:00
资讯
新帖
简况
智飞生物三季度多项“第一”:营收首降、存货新高、债务规模最大,为何坦承市场推广工作不足?
华夏时报 · 11-02 09:28
智飞生物三季度多项“第一”:营收首降、存货新高、债务规模最大,为何坦承市场推广工作不足?
智飞生物:10月30日接受机构调研,中信建投、国盛证券等多家机构参与
证券之星 · 10-31 11:07
智飞生物:10月30日接受机构调研,中信建投、国盛证券等多家机构参与
“疫苗一哥”智飞生物难逃“业绩劫”
市场资讯 · 10-28
“疫苗一哥”智飞生物难逃“业绩劫”
智飞生物(300122)2024年三季报简析:净利润减67.07%,应收账款上升
证券之星 · 10-27
智飞生物(300122)2024年三季报简析:净利润减67.07%,应收账款上升
智飞生物(300122)10月10日股东户数11.82万户,较上期增加0.17%
证券之星 · 10-26
智飞生物(300122)10月10日股东户数11.82万户,较上期增加0.17%
图解智飞生物三季报:第三季度单季净利润同比减103.69%
证券之星 · 10-26
图解智飞生物三季报:第三季度单季净利润同比减103.69%
智飞生物(300122.SZ):流感病毒裂解疫苗申请生产注册获受理
智通财经 · 10-25
智飞生物(300122.SZ):流感病毒裂解疫苗申请生产注册获受理
智飞生物(300122.SZ):佐剂四价流感疫苗获临床试验批准
智通财经 · 10-25
智飞生物(300122.SZ):佐剂四价流感疫苗获临床试验批准
智飞生物(300122.SZ)发布前三季度业绩,净利润21.51亿元,下降67.07%
智通财经 · 10-25
智飞生物(300122.SZ)发布前三季度业绩,净利润21.51亿元,下降67.07%
智飞生物最新公告:四价流感病毒裂解疫苗(ZFA02佐剂)获批临床试验
证券之星 · 10-25
智飞生物最新公告:四价流感病毒裂解疫苗(ZFA02佐剂)获批临床试验
中国智飞生物三季度同比由盈转为亏损0.8亿元,营收骤降近七成
路透中文 · 10-25
中国智飞生物三季度同比由盈转为亏损0.8亿元,营收骤降近七成
智飞生物:四价流感疫苗获临床试验批准
美港电讯 · 10-25
智飞生物:四价流感疫苗获临床试验批准
A股生物制品板块震荡走高,特宝生物、三生国健涨超10%,荣昌生物、诺唯赞、智飞生物、百奥泰等多股大涨。
美港电讯 · 10-18
A股生物制品板块震荡走高,特宝生物、三生国健涨超10%,荣昌生物、诺唯赞、智飞生物、百奥泰等多股大涨。
智飞生物(300122.SZ):冻干人用狂犬病疫苗(人二倍体细胞)申请生产注册获得受理
智通财经 · 10-16
智飞生物(300122.SZ):冻干人用狂犬病疫苗(人二倍体细胞)申请生产注册获得受理
智飞生物最新公告:子公司冻干人用狂犬病疫苗(人二倍体细胞)申请生产注册获受理
证券之星 · 10-16
智飞生物最新公告:子公司冻干人用狂犬病疫苗(人二倍体细胞)申请生产注册获受理
智飞生物(300122)10月15日主力资金净卖出8947.38万元
证券之星 · 10-16
智飞生物(300122)10月15日主力资金净卖出8947.38万元
智飞生物(300122)10月10日股东户数11.82万户,较上期增加5.42%
证券之星 · 10-14
智飞生物(300122)10月10日股东户数11.82万户,较上期增加5.42%
重发-《股市简讯》中国股市创业板指数一度挫逾5%,暴涨六日后陷入回调
Reuters · 10-11
重发-《股市简讯》中国股市创业板指数一度挫逾5%,暴涨六日后陷入回调
10月10日智飞生物跌5.08%,招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 10-10
10月10日智飞生物跌5.08%,招商国证生物医药指数(LOF)C基金重仓该股
智飞生物(300122.SZ):四价流感病毒裂解疫苗(儿童型)申请生产注册获受理
智通财经 · 10-09
智飞生物(300122.SZ):四价流感病毒裂解疫苗(儿童型)申请生产注册获受理
加载更多
公司概况
公司名称:
重庆智飞生物制品股份有限公司
所属行业:
医药制造业
上市日期:
2010-09-28
主营业务:
重庆智飞生物制品股份有限公司是一家从事疫苗、生物制品的研发、生产和销售的公司;公司的主要产品包括预防流脑、宫颈癌、肺炎、轮状病毒等传染病的疫苗产品,也涵盖提供结核感染诊断、预防、治疗有效解决方案的药品。公司自成立以来,一贯注重研发与技术创新,通过十余年稳步增长的研发投入和持续深入的研发活动,形成了行业较领先的研发技术能力,并为公司可持续发展提供了技术根基。先后参与了科技部“863计划”,“现代医学技术”项目,科技部重大新药创制,国家新药创制重大专项等20余项国家级,省部级项目。
发行价格:
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":28.25,"timestamp":1730444634000,"preClose":28.38,"halted":0,"volume":41745065,"delay":0,"floatShares":1414000000,"shares":2394000000,"eps":1.5416,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.13,"latestTime":"11-01 15:00:00","open":28.17,"high":28.76,"low":27.62,"amount":1178000000,"amplitude":0.0402,"askPrice":28.26,"askSize":160,"bidPrice":28.25,"bidSize":345,"shortable":0,"etf":0,"ttmEps":1.5416,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1730683800000},"adr":0,"adjPreClose":28.38,"symbolType":"stock","openAndCloseTimeList":[[1730424600000,1730431800000],[1730437200000,1730444400000]],"highLimit":31.22,"lowLimit":25.54,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"pbRate":2.16,"roa":"--","roe":"6.78%","epsLYR":3.3624,"committee":0.297155,"marketValue":67625000000,"floatMarketCap":39954000000,"peRate":18.325117,"changeRate":-0.0046,"turnoverRate":0.0295,"status":1},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2480963468","title":"智飞生物三季度多项“第一”:营收首降、存货新高、债务规模最大,为何坦承市场推广工作不足?","url":"https://stock-news.laohu8.com/highlight/detail?id=2480963468","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480963468?lang=zh_cn&edition=full","pubTime":"2024-11-02 09:28","pubTimestamp":1730510880,"startTime":"0","endTime":"0","summary":"与以往不同的是,此番智飞生物拿下了多项“第一”,例如营收首次下滑、存货创历史新高、短期债务规模最大等等。先看智飞生物在市场推广方面做了哪些工作。可以看出,智飞生物在市场推广上的投入逐年增加,反映了其对市场推广工作的高度重视。而今年前三季度,智飞生物经营性现金流大幅流出30.65亿元,实属罕见。大规模举债下,智飞生物前三季度的利息费用已经超过了去年全年。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-11-02/doc-incurtuh2360297.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-02/doc-incurtuh2360297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300122"],"gpt_icon":0},{"id":"2479316710","title":"智飞生物:10月30日接受机构调研,中信建投、国盛证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479316710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479316710?lang=zh_cn&edition=full","pubTime":"2024-10-31 11:07","pubTimestamp":1730344027,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年10月30日智飞生物发布公告称公司于2024年10月30日接受机构调研,中信建投、国盛证券、睿远基金、申万菱信参与。适龄女性接种 HPV 疫苗具有必要性。根据世界卫生组织发布的《2024 年全球结核病报告》,2023年全球因结核病死亡人数为 125 万,结核病重返全球单一传染病死因首位。公司积极响应世界卫生组织提出的终止结核病战略,积极推动公司结核病诊疗产品在结核病高负担国家的注册上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100019222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","300122","LU2580892789.USD","LU2148510915.USD","LU1328615791.USD","LU2580892862.HKD","BK0239","BK0046","BK0188","BK0196","LU1064131003.USD","601066","BK0276","161027","BK0077"],"gpt_icon":0},{"id":"2478810073","title":"“疫苗一哥”智飞生物难逃“业绩劫”","url":"https://stock-news.laohu8.com/highlight/detail?id=2478810073","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478810073?lang=zh_cn&edition=full","pubTime":"2024-10-28 20:40","pubTimestamp":1730119200,"startTime":"0","endTime":"0","summary":" 浓眉大眼的疫苗一哥智飞生物,也难逃三季度的业绩雷。财报显示,智飞生物单季度归母净利润8年来首次出现亏损,亏损的原因则是HPV疫苗收入未达预期。而随着HPV疫苗竞争的白热化,智飞生物的代理生意红利将逐渐消退。 此次业绩“暴雷”,打破了智飞生物靠代理生意“躺平”的幻想,摆在公司面前的,除了业绩下滑,还有存货翻倍、短期借款大幅增加、经营现金流转负的经营压力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-10-28/doc-incucmqv8551025.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-10-28/doc-incucmqv8551025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2580892862.HKD","BK0239","BK0077","BK0046","BK0196","LU1064131003.USD","LU1064130708.USD","LU2580892789.USD","159646","LU1328615791.USD","300122","LU2148510915.USD","BK0188"],"gpt_icon":0},{"id":"2478718482","title":"智飞生物(300122)2024年三季报简析:净利润减67.07%,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2478718482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478718482?lang=zh_cn&edition=full","pubTime":"2024-10-27 10:58","pubTimestamp":1729997887,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期智飞生物发布2024年三季报。截至本报告期末,公司营业总收入227.86亿元,同比下降41.98%,归母净利润21.51亿元,同比下降67.07%。本报告期智飞生物应收账款上升,应收账款同比增幅达41.78%。去年的净利率为15.25%,算上全部成本后,公司产品或服务的附加值高。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700011285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"gpt_icon":0},{"id":"2478963942","title":"智飞生物(300122)10月10日股东户数11.82万户,较上期增加0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478963942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478963942?lang=zh_cn&edition=full","pubTime":"2024-10-26 17:03","pubTimestamp":1729933404,"startTime":"0","endTime":"0","summary":"证券之星消息,近日智飞生物披露,截至2024年10月10日公司股东户数为11.82万户,较9月30日增加198.0户,增幅为0.17%。在生物制品行业个股中,智飞生物股东户数高于行业平均水平,截至10月10日,生物制品行业平均股东户数为3.35万户。根据统计,智飞生物2024年9月30日至2024年10月10日,主力资金净流出8.08亿元,游资资金净流入1.93亿元,散户资金净流入6.15亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600008550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0077","BK0239","BK0188","BK0046","LU1064130708.USD","LU1328615791.USD","LU2580892789.USD","BK0196","LU2580892862.HKD","LU1064131003.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2478614951","title":"图解智飞生物三季报:第三季度单季净利润同比减103.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478614951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478614951?lang=zh_cn&edition=full","pubTime":"2024-10-26 00:51","pubTimestamp":1729875063,"startTime":"0","endTime":"0","summary":"证券之星消息,智飞生物2024年三季报显示,公司主营收入227.86亿元,同比下降41.98%;归母净利润21.51亿元,同比下降67.07%;扣非净利润21.43亿元,同比下降66.41%;其中2024年第三季度,公司单季度主营收入45.28亿元,同比下降69.46%;单季度归母净利润-8369.64万元,同比下降103.69%;单季度扣非净利润-8741.52万元,同比下降104.03%;负债率41.46%,财务费用5431.14万元,毛利率27.23%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102600000594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"gpt_icon":0},{"id":"2478937274","title":"智飞生物(300122.SZ):流感病毒裂解疫苗申请生产注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2478937274","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478937274?lang=zh_cn&edition=full","pubTime":"2024-10-25 23:25","pubTimestamp":1729869908,"startTime":"0","endTime":"0","summary":"智通财经APP讯,智飞生物(300122.SZ)公告,公司近日收到全资子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)报告,由智飞龙科马自主研发的流感病毒裂解疫苗申请生产注册获得国家药品监督管理局出具的《受理通知书》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","300122","LU1064130708.USD","159646","LU1064131003.USD","LU2580892862.HKD","BK0196","BK0077","LU1328615791.USD","BK0188","LU2580892789.USD","LU2148510915.USD","BK0239"],"gpt_icon":0},{"id":"2478937119","title":"智飞生物(300122.SZ):佐剂四价流感疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2478937119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478937119?lang=zh_cn&edition=full","pubTime":"2024-10-25 23:22","pubTimestamp":1729869735,"startTime":"0","endTime":"0","summary":"智通财经APP讯,智飞生物(300122.SZ)公告,由全资子公司安徽智飞龙科马生物制药有限公司研发的四价流感病毒裂解疫苗(ZFA02佐剂)(简称“佐剂四价流感疫苗”)获得国家药品监督管理局药物临床试验批准通知书同意开展预防疫苗相关型别流感病毒引起的流行性感冒的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK1576","BK1141","BK0077","LU2580892862.HKD","LU1064130708.USD","BK0046","BK0188","BK1583","LU1064131003.USD","300122","LU1328615791.USD","LU2580892789.USD","BK0239","LU2148510915.USD","03347"],"gpt_icon":0},{"id":"2478937111","title":"智飞生物(300122.SZ)发布前三季度业绩,净利润21.51亿元,下降67.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478937111","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478937111?lang=zh_cn&edition=full","pubTime":"2024-10-25 23:17","pubTimestamp":1729869421,"startTime":"0","endTime":"0","summary":"智通财经APP讯,智飞生物(300122.SZ)发布2024年三季度报告,该公司前三季度营业收入为227.86亿元,同比减少41.98%。归属于上市公司股东的净利润为21.51亿元,同比减少67.07%。归属于上市公司股东的扣除非经常性损益的净利润为21.43亿元,同比减少66.41%。基本每股收益为0.8976元。同时,公司披露2024年中期利润分配方案,拟向全体股东每10股派发现金红利2.00元(含税)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300122"],"gpt_icon":0},{"id":"2478983989","title":"智飞生物最新公告:四价流感病毒裂解疫苗(ZFA02佐剂)获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2478983989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478983989?lang=zh_cn&edition=full","pubTime":"2024-10-25 20:02","pubTimestamp":1729857776,"startTime":"0","endTime":"0","summary":"智飞生物公告,公司全资子公司智飞龙科马研发的四价流感病毒裂解疫苗(ZFA02佐剂)获得临床试验批准通知书。同时,智飞龙科马自主研发的流感病毒裂解疫苗申请生产注册获得受理。公司同日披露三季报,2024年前三季度公司实现净利润21.51亿元,同比减少67.07%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500040466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1583","BK0196","BK0046","LU2580892789.USD","03347","LU1328615791.USD","BK1576","LU1064131003.USD","LU2148510915.USD","BK1141","LU1064130708.USD","LU2580892862.HKD","BK0188","300122","159646","BK0077"],"gpt_icon":0},{"id":"2478898809","title":"中国智飞生物三季度同比由盈转为亏损0.8亿元,营收骤降近七成","url":"https://stock-news.laohu8.com/highlight/detail?id=2478898809","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478898809?lang=zh_cn&edition=full","pubTime":"2024-10-25 19:58","pubTimestamp":1729857494,"startTime":"0","endTime":"0","summary":"路透北京10月25日 - 中国疫苗生产商--智飞生物300122.SZ周五公布,三季度录得净亏损8,369.6万元人民币,同比由盈转亏,上年同期为净利润22.7亿元;报告期内营收45.3亿元,同比降69.5%。财报显示,前三季度,公司销售费用19.4亿元,同比增约5%。9月中旬,智飞生物公告称,董事会选举蒋仁生为公司第六届董事会董事长。智飞生物周五收涨0.7%,今年迄今累跌近五成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241025:nL4T3M10KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300122"],"gpt_icon":0},{"id":"2478983078","title":"智飞生物:四价流感疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2478983078","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478983078?lang=zh_cn&edition=full","pubTime":"2024-10-25 19:33","pubTimestamp":1729856016,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0046","BK0077","159646","LU1328615791.USD","BK1583","LU2148510915.USD","LU2580892862.HKD","BK1576","LU2580892789.USD","BK0239","BK1141","03347","BK0196","LU1064131003.USD","BK0188","300122","LU1064130708.USD"],"gpt_icon":0},{"id":"2476297624","title":"A股生物制品板块震荡走高,特宝生物、三生国健涨超10%,荣昌生物、诺唯赞、智飞生物、百奥泰等多股大涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2476297624","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476297624?lang=zh_cn&edition=full","pubTime":"2024-10-18 14:29","pubTimestamp":1729232967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2580892789.USD","LU1969619763.USD","LU1064130708.USD","BK0188","LU2580892862.HKD","399300","LU2328871848.SGD","BK0046","BK0196","688336","688331","688278","09995","LU1064131003.USD","BK0239","300122","BK0216","688105","BK0077","688177","LU2148510915.USD","LU1328615791.USD","BK1161","BK1583","159982","BK1574"],"gpt_icon":0},{"id":"2475096391","title":"智飞生物(300122.SZ):冻干人用狂犬病疫苗(人二倍体细胞)申请生产注册获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2475096391","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475096391?lang=zh_cn&edition=full","pubTime":"2024-10-16 18:54","pubTimestamp":1729076055,"startTime":"0","endTime":"0","summary":"智通财经APP讯,智飞生物(300122.SZ)发布公告,公司于近日收到全资子公司安徽智飞龙科马生物制药有限公司(以下简称“智飞龙科马”)报告,由智飞龙科马自主研发的冻干人用狂犬病疫苗(人二倍体细胞)申请生产注册获得国家药品监督管理局出具的《受理通知书》(受理号:CXSS2400112)。本次申请生产注册获得受理的冻干人用狂犬病疫苗(人二倍体细胞)以人二倍体细胞为培养基质,接种后可预防狂犬病。截至公告日,经查询国家药品监督管理局网站,国内有2款获批上市的冻干人用狂犬病疫苗(人二倍体细胞)。若该项目进展顺利,将进一步丰富公司病毒类疫苗品种,完善公司产品布局,强化公司的市场竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1194926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1064131003.USD","159646","LU2580892862.HKD","300122","LU2148510915.USD","LU2580892789.USD","BK0188","BK0046","LU1328615791.USD","LU1064130708.USD","BK0077","BK0196"],"gpt_icon":0},{"id":"2475963110","title":"智飞生物最新公告:子公司冻干人用狂犬病疫苗(人二倍体细胞)申请生产注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2475963110","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475963110?lang=zh_cn&edition=full","pubTime":"2024-10-16 18:51","pubTimestamp":1729075864,"startTime":"0","endTime":"0","summary":"智飞生物公告,子公司智飞龙科马自主研发的冻干人用狂犬病疫苗(人二倍体细胞)申请生产注册获得国家药品监督管理局出具的《受理通知书》。若本项目进展顺利,将进一步丰富公司病毒类疫苗品种,完善公司产品布局,强化公司的市场竞争优势。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101600029781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0077","BK0196","LU1064130708.USD","BK0046","LU2148510915.USD","300122","LU2580892789.USD","BK0188","159646","BK0239","LU2580892862.HKD","LU1328615791.USD"],"gpt_icon":0},{"id":"2475275629","title":"智飞生物(300122)10月15日主力资金净卖出8947.38万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475275629","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475275629?lang=zh_cn&edition=full","pubTime":"2024-10-16 09:59","pubTimestamp":1729043998,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月15日收盘,智飞生物报收于30.43元,下跌4.7%,换手率3.29%,成交量46.47万手,成交额14.49亿元。近5日资金流向一览见下表:智飞生物融资融券信息显示,融资方面,当日融资买入1.73亿元,融资偿还1.44亿元,融资净买入2898.86万元。智飞生物主营业务:疫苗、生物制品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101600007679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0196","LU2148510915.USD","BK0239","LU2580892862.HKD","LU2580892789.USD","BK0046","LU1064131003.USD","300122","LU1064130708.USD","LU1328615791.USD","BK0077"],"gpt_icon":0},{"id":"2475358322","title":"智飞生物(300122)10月10日股东户数11.82万户,较上期增加5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475358322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475358322?lang=zh_cn&edition=full","pubTime":"2024-10-14 17:04","pubTimestamp":1728896669,"startTime":"0","endTime":"0","summary":"证券之星消息,近日智飞生物披露,截至2024年10月10日公司股东户数为11.82万户,较9月20日增加6075.0户,增幅为5.42%。在生物制品行业个股中,智飞生物股东户数高于行业平均水平,截至10月10日,生物制品行业平均股东户数为3.36万户。根据统计,智飞生物2024年9月20日至2024年10月10日,主力资金净流出6.76亿元,游资资金净流入1.25亿元,散户资金净流入5.51亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101400022611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1064130708.USD","LU2580892862.HKD","LU2148510915.USD","300122","LU2580892789.USD","BK0077","BK0196","LU1064131003.USD","BK0046","BK0188","LU1328615791.USD"],"gpt_icon":0},{"id":"2474087964","title":"重发-《股市简讯》中国股市创业板指数一度挫逾5%,暴涨六日后陷入回调","url":"https://stock-news.laohu8.com/highlight/detail?id=2474087964","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474087964?lang=zh_cn&edition=full","pubTime":"2024-10-11 10:56","pubTimestamp":1728615384,"startTime":"0","endTime":"0","summary":" * 中国股市创业板指数 周五早盘一度跌5.5%,在连续暴涨六日后,创业板指数陷入回调。* 主要权重股--宁德时代 跌逾4%,爱美客 、智飞生物 挫7%上下。* 创业板指数节后交易首日创下单日最大纪录涨幅,但此后便陷入调整,已连续二个交易日下挫。* 强震之后的余波,仍然冲击着中国股市,政策的不确定性成为投资者心中最为高悬的一柄利剑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0463099449.HKD","LU2580892862.HKD","300750","LU1997244956.HKD","LU1188198961.HKD","LU0359201612.USD","LU0405327148.USD","BK0224","LU1146622755.USD","BK0188","399001","EVS.SI","LU1961090484.USD","399006","LU0269904917.USD","BK0239","LU0823414478.USD","BK0077","LU1655091616.SGD","LU0181495838.USD","LU2238339852.HKD","LU0348805143.USD","LU0505663152.USD","LU1831875114.USD","LU0502904849.HKD","LU0572944931.SGD","LU2294711713.HKD","LU1580142542.USD","300122","LU0828237510.HKD","300896","LU1023057109.AUD","LU1979443071.USD","LU0259732245.USD","LU0823426480.USD","LU2580892789.USD","LU0455707207.USD","LU0823426308.USD","LU0231483743.USD","LU0823414551.USD","LU1720050803.USD","LU0405327494.USD","LU0509642566.USD","LU1997245094.SGD","LU1997245177.USD","LU2153591404.USD","LU1064130708.USD","LU2249611893.SGD","LU1794554557.SGD","LU0228659784.USD"],"gpt_icon":0},{"id":"2474679357","title":"10月10日智飞生物跌5.08%,招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474679357","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474679357?lang=zh_cn&edition=full","pubTime":"2024-10-10 16:13","pubTimestamp":1728548019,"startTime":"0","endTime":"0","summary":"证券之星消息,10月10日智飞生物跌5.08%,收盘报34.73元,换手率5.27%,成交量74.54万手,成交额26.37亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共73家,其中持有数量最多的公募基金为招商国证生物医药指数C。招商国证生物医药指数C目前规模为18.34亿元,最新净值0.4287,较上一交易日下跌7.95%,近一年下跌15.11%。招商国证生物医药指数C的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101000027115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","300122","LU2148510915.USD","BK0196","BK0046","LU1064130708.USD","BK0239","BK0077","LU2580892789.USD","BK0188","LU1328615791.USD","399441","LU1064131003.USD","161726"],"gpt_icon":0},{"id":"2474578245","title":"智飞生物(300122.SZ):四价流感病毒裂解疫苗(儿童型)申请生产注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2474578245","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474578245?lang=zh_cn&edition=full","pubTime":"2024-10-09 19:11","pubTimestamp":1728472314,"startTime":"0","endTime":"0","summary":"智通财经APP讯,智飞生物(300122.SZ)公告,公司近日收到全资子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)报告,由智飞龙科马自主研发的四价流感病毒裂解疫苗(儿童型)申请生产注册获得国家药品监督管理局出具的《受理通知书》。本次生产注册获得受理的四价流感病毒裂解疫苗(儿童型),接种对象为6-35月龄儿童,可刺激机体产生抗流感病毒的免疫力,用于预防疫苗相关型别的流感病毒引起的流行性感冒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1191901.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0077","LU2580892862.HKD","LU1064130708.USD","BK0046","LU1064131003.USD","300122","LU1328615791.USD","LU2580892789.USD","BK0239","LU2148510915.USD","BK0188","159646"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-09-28","address":"重庆市江北区庆云路1号50层","stockEarnings":[{"period":"1week","weight":-0.1246},{"period":"1month","weight":-0.1537},{"period":"3month","weight":0.0573},{"period":"6month","weight":-0.1707},{"period":"1year","weight":-0.5469},{"period":"ytd","weight":-0.5237}],"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","perCapita":"11250股","boardName":"医药制造业","registeredCapital":"239378万元","compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.1262},{"period":"6month","weight":0.0538},{"period":"1year","weight":0.0873},{"period":"ytd","weight":0.0999}],"survey":" 重庆智飞生物制品股份有限公司是一家从事疫苗、生物制品的研发、生产和销售的公司;公司的主要产品包括预防流脑、宫颈癌、肺炎、轮状病毒等传染病的疫苗产品,也涵盖提供结核感染诊断、预防、治疗有效解决方案的药品。公司自成立以来,一贯注重研发与技术创新,通过十余年稳步增长的研发投入和持续深入的研发活动,形成了行业较领先的研发技术能力,并为公司可持续发展提供了技术根基。先后参与了科技部“863计划”,“现代医学技术”项目,科技部重大新药创制,国家新药创制重大专项等20余项国家级,省部级项目。","serverTime":1730571732903,"listedPrice":37.98,"stockholders":"125715人(较上一季度增加6.37%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}